Back to trial
Eligibility Pre-Screening
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
This is a simplified pre-screening tool. Your answers help estimate whether you might qualify, but only the research team can confirm your eligibility. This is not medical advice.
Question 1 of 80%